echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > Preface Zhenda Li Yuan: Entering Sequoia China Smart Medical Genomics Incubator (driven by Meena technology), opening a new stage of multi-omics industry collaboration

    Preface Zhenda Li Yuan: Entering Sequoia China Smart Medical Genomics Incubator (driven by Meena technology), opening a new stage of multi-omics industry collaboration

    • Last Update: 2022-01-04
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com



    Shanghai, November 23, 2021/PRNewswire/ - On November 17, the Sequoia China Smart Medical Genomics Incubator (Driven by Mena Technology) project was officially launched
    .
    This project not only follows the "14th Five-Year Plan" vision of "genes and biotechnology becoming one of the key frontiers of national strategic science and technology", but also receives the gene industry due to the blessing of Sequoia China and Illumina (Inmena).
    Of no small concern

    .


    The settled companies come to the stage to accept the notification of selection: Left-Mozhuo Biotech founder and CEO Pei Hao; Middle-Sequoia China Managing Director Cao Yibo; Right-Xu Zhenda General Manager Li Yuan

    “This method is actually a bit similar to the Internet innovation model,” said Dr.
    Li Yuan, the general manager of Xuzhenda Biotechnology, one of the first batch of incubation companies.
    “The track of genetic testing is long and wide enough.
    If you make a little achievement in one paragraph, you are very likely to create a larger market

    .
    "

    In other words, this is not a "winner takes all" pattern
    .
    Start-ups entering the incubator will have the opportunity to seek a broader platform and expansion space

    .

    For Xu Zhenda, who is in the initial stage of acceleration, getting a few places can prove its qualifications and potential in the field of genetic sciences on the one hand , and on the other hand , it can be used to clean up the experience of the next new project.
    Worries

    .
    Dr.
    Li Yuan expects that Xu Zhenda can find more uses for its integration capabilities

    .

    It emerged as the official "settled incubators three one minute"

    The Sequoia China Smart Medical Genomics Incubator (driven by Meina's technology) project just hit the news, and it quickly aroused the interest of dozens of upstream and downstream genetic start-ups
    .
    In three months, nearly 60 startup companies actively signed up.
    After multiple rounds of screening, Xu Zhenda was fortunate to become one of the three incubating companies in the first phase

    .

    The reason why Xu Zhenda was able to stand out from this nationwide selection and become the lucky "one-third" is largely because Xu Zhenda proposed a good "model", which was received by the judges and experts.
    Recognized

    .
    And this "model" in Dr.
    Li Yuan's mouth is far more extensive than the genetic testing service itself

    .

    "It can be seen that the industry has encountered some disease mechanisms and drug targets that could not be discovered by genomics alone.
    With the development of multi-omics, there has been a turning point

    .
    This is the transformation that multi-omics has brought to the upstream of the biopharmaceutical industry.

    Secondly, after all, multi-omics is based on genomics.
    The technological advancement of multi-omics itself will also drive the progress and demand expansion of genomics.
    Further

    expansion, we hope to cooperate with pharmaceutical companies, biotechnology companies and research institutes.
    The institutions and other institutions jointly excavate these multi-omics superimposed data, and ultimately drive the transformation of results

    .
    " Dr.
    Li Yuan further explained

    .

    In October 2020, an article "Genomic and drug target evaluation of 90 cardiovascular proteins in 30,931 individuals" published on Nature Metabolism , to some extent confirmed the prospects for the direction of order
    .
    The researchers mapped and replicated protein quantitative trait loci (pQTL) of 90 cardiovascular proteins in 30,000 individuals, and finally obtained 451 pQTLs for 85 proteins

    .
    The study identified 11 previously untargeted proteins that are causally related to related diseases, verified the practicality of large-scale proteomic genetics maps, and provided resources for the precise study of circulating proteins in human health in the future

    .

    It is worth noting that the project that Xu Zhenda plans to launch this time in the incubator is related to proteomics
    .
    On November 17, Dr.
    Li Yuan announced the 1,000-person cohort project at the opening ceremony of the Sequoia China Smart Medical Genomics Incubator (driven by Mena technology)

    .


    Xu Zhenda General Manager Li Yuan

    "Based on the model created by this project, we hope to provide a high-quality data platform that links the upstream and downstream of the industry chain and promotes the research and development of innovative drugs
    .
    " Dr.
    Li Yuan summarized, "(Xuzhenda) acts like a bridge

    .
    "

    In addition to model innovation, Xuzhenda can be recognized by Sequoia China and Illumina, and it is also inseparable from an efficient operation management team
    .

    Dr.
    Li Yuan stated that although Xu Zhenda was established for only one year, the core team is composed of senior practitioners in the field of biomedicine and doctors and senior researchers from well-known universities at home and abroad.
    More than 10 years of experience in the industry

    .
    "

    It can be expected that the superposition of these advantages will make the incubator's empowerment effect more significant
    .

    Accelerate cooperation and promote the implementation of new technologies with multi-omics

    In the past, it seemed more of a gimmick to talk about multi-group learning
    .
    However, with the continuous enrichment of various omics testing methods surrounding the central law, people deeply feel that the previous conclusions based on a single omics may be "only see the trees but not the forest"

    .
    "Omics" is a holistic research idea that aims to identify a series of markers worthy of targeted research

    .
    As a multi-omics research and clinical service provider, Xu Zhenda is gradually filling its own multi-omics research platform

    .

    In May of this year, Xu Zhenda reached a strategic cooperation with Olink
    .
    "The use of technologies like Olink for proteomics data analysis is still a minority in China

    .
    " Dr.
    Li Yuan
    said , "At this stage, proteomics testing is one of the key promotion sections of XZD
    .
    But as a high With a high-quality multi-omics service platform, Xu Zhenda’s business breakthroughs are not only reflected in proteomics

    .
    "

    At the end of October, Xu Zhenda reached an agreement with Mission Bio, a pioneer in single-cell DNA analysis and precise genomics, and became its preferred service provider in China
    .
    The two parties will jointly promote continuous innovation in the field of tumor cell therapy on a global scale, and achieve precise tumor discovery and precise detection technology

    .


    Settled companies in the incubator laboratory: Left-Xu Zhenda General Manager Li Yuan; Middle-Inmana Global Startup Support Platform Greater China Leader Lin Ziyao; Right-Mozhuo Bio-Founder and CEO

    Dr.
    Li Yuan said that being selected as the Sequoia China Smart Medical Genomics Incubator (driven by Mena’s technology) “feels another expansion of alumni”, allowing industry colleagues to gain deeper exchanges and cooperation and jointly promote the development of innovative drugs.
    Production

    .

    For Xu Zhenda, what the incubator provides is not only the NGS shared experimental platform, independent laboratory, office, conference, training and other basic functional facilities needed by startups, but more importantly from the industry's leading investment institution Sequoia China With professional entrepreneurial counseling and extensive industry collaboration behind Inmena, a leading company in the gene industry
    .

    "Xu Zhenda's attitude is always open.
    Based on the field of drug research and development, we will expand to more innovative applications including targeted therapy, immunotherapy, cell and gene therapy, etc.
    , and hope to work with our peers.
    , To help the transformation and upgrading of China's biomedicine

    .
    " Dr.
    Li Yuan finally said

    .



    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.